NFKB1 and Miyoshi myopathy: Our current focus is on celastrol, a compound extracted from Tripterygium Wilfordii that has shown promising anticancer effects in various cancers, including MM, by inhibiting NF‐κb and STAT3 activation[10] or proteasome activity.[11] Additionally, celastrol has been shown to improve the BM microenvironment,[12] making it a precious compound for treating MM.